Cohort study shows improved safety and efficacy of aponermin bridging therapy in relapsed/refractory multiple myeloma, indicating better CAR-T cell outcomes.
Key Points
This research aims to evaluate the safety and efficacy of aponermin-based regimens as bridging therapy before CAR-T cell treatment in relapsed/refractory multiple myeloma.
Retrospective cohort study design
Involved RRMM patients receiving aponermin-based chemotherapy after leukapheresis
Patients underwent lymphodepletion with fludarabine and cyclophosphamide before BCMA CAR-T infusion
Overall response rate after bridging therapy was 41.7%
Complete response was achieved in 7.1% of patients
Median progression-free survival after CAR-T was 6.43 months
Bridging therapy maintained a favorable safety profile with minimal adverse effects